~nacea Biotec

May 30, 2023

!hhOVt::...tt'Oht'h support: of tt'fe

The Manager, Listing Department

BSE Limited

The National Stock Exchange of India Ltd.

Corporate Relationship Department,

Exchange Plaza, Bandra Kurla Complex,

Phiroze Jeejeebhoy Towers,

Bandra (E), Mumbai - 400 051

Dalal Street, Mumbai - 400 001

NSE Symbol: PANACEABIO

BSE Scrip Code: 531349

Reg.: Outcome of Board Meeting

Dear Sir/Madam,

In continuation to our letter dated May 15, 2023, we would like to inform that pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), the Board of Directors of the Company has, at its meeting held today, i.e. May 30, 2023, inter-alia, considered and approved the Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2023. The same were also reviewed by the Audit Committee in its meeting held on May 29, 2023.

A copy of the same along with the Auditors' Report is enclosed herewith as Annexure - A.

Further, we would also like to submit as under:

  1. in compliance with the provisions of Regulation 33(3)(d) of the SEBI LODR Regulations and SEBI Circular No. CIRlCFD/CMD/56/2016 dated May 27, 2016, we hereby declare that the Auditors' Report on the aforesaid Standalone and Consolidated Audited Financial Results for the financial Year ended March 31, 2023 is with unmodified opinion;
  2. pursuant to Regulation 46(2)(1) of SEBI LODR Regulations, the aforesaid financial results are being uploaded on the website of the Company i.e. www.panaceabiotec.com;
  3. pursuant to Regulation 47(1 )(b) of SEBI LODR Regulations, the Extract of Statement of above Audited Financial Results is being sent for publication in newspapers; and
  1. in view of operational losses, the Board of Directors has not recommended any dividend on the Preference as well as Equity Shares of the Company for the financial year ended March 31, 2023.

The meeting of the Board of Directors commenced at 11 :00 A.M. and concluded at 2:30 P.M.

Panacea Biotec Ltd.

CIN:L33117PB1984PLC022350

81 Extn. /G3, Mohan Co-op Indl. Estate, Mathura Road, New Delhi -110044 Email: vinodgoel@panaceabiotec.com Phone: 0.1.0. +91-11-41679015

Fax: +91-11-4167 9070

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.

e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

~ ,

'j Panacea Blotec

: •..•• , •. '''~

.~ ' •. 'Nlj.'1··.·~'I"'of!(/

•..•

Particulars

Total income from operations

Net Profit / (Loss) for the period/year (hefore tax, exceptional and/or extraordinary item) Net Profit / (Loss) for the period/yearbefore tax (after exceptional and/or extraordinary item) Net Profit / (Loss) for the period/yearafter tax (after exceptional and/or extraordinary item) Total comprehensive income/(loss)for the period/year (comprising of profit/(loss) for the period/year (after tax) and other comprehensiveincome (after tax))

Equity Share Capital (face value ofRe.1 per share) Earning/(Ioss) per share, (annualised, except for quarters):

Basic and Diluted

  • ---

(Rs. in Lakh except per share)

Extract of Standalone and Consolidated Financial Results (Audited)

for the Quarter and Year Ended March 31, 2023

Standalone

Consolidated

Quarter Ended

Year Ended

Quarter Ended

Year Ended

March 31,

December

March 31,

March 31,

March 31,

March 31,

December

March 31,

March 31,

March 31,

2023

31,2022

2022

2023

2022

2023

31

2022

2022

2023

2022

Audited

Unaudited

Audited

Audited

Audited

Audited

Unaudited

Audited

Audited

Audited

7,502

7,197

4,150

25,707

23,550

12,893

11,520

14,073

45,995

66,123

510

1,324

(2,531

(6,275)

(9,358)

(117)

(533)

(6,795)

(8,986)

(22,685

510

1,324

(2,531)

(6,275)

(9,358)

1,821

2,244

160,826

1,280

144,936

(1,969)

1,324

(2,531)

(8,754)

(9,358)

(1,268)

1,937

123,747

(3,375)

107,834

(2,149)

1,324

(2,463)

(8,944)

(9,308)

(1,179)

1,921

123,710

(3,347)

107,794

613

613

613

613

613

613

613

613

613

613

(3.21)

2.16

(4.13)

(14.29)

(15.28)

(2.07)

3.16

202.03

(5.51)

176.05

Notes:

The above is an extract of the detailed format of Quarterly and year ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBl (ListingObligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Year ended Financial Results is available on the Stock Exchanges websites, NSE- http://www.nseindia.com, BSE- http://www.bseindia.com and is also available on the Company's website, http://www.panaceabiotec.com.

  1. The above financial results were reviewed by the Audit Committee of the Board and approved by the Board of Directors at their meetings held on May 29, 2023 and May 30,2023 respectively.
  2. The financial results have been prepared in accordance with the recognition and measurementprinciples of applicable Indian Accounting Standard ("IND-AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in section 133 of the CompaniesAct, 2013.
  3. Previous period / year amounts have been regrouped/ reclassified to make them comparable with those of current period/year.

For and on behalfof the Board of Directors of

Panacea Biotec Limited

Place: New Delhi

L

Date: May 30, 2023

~,~

Chairman & Managlng "'~~

Panacea Biotec Limited

Regd. Office: Ambala-ChandigarhHighway, Lalru- 14050 I, Punjab

CrN: L33117PB1984PLC022350 - Ph. No. 91-11-41679000, Fax: 91-11-41679070,

Website: https.z/www.panacea-biotec.com,E-mail: Corporate@panaceabiotec.com

~

Panacea Biotec

'.

S.NoParticulars

  1. Income:
    1. Revenue from operations
    2. Other income

Total Income

  1. Expenditure:
    1. Cost of raw and packing materials consumed
    2. Purchase of traded goods
    3. Changes in inventories of finished goods. work-in-progress and stock-in-trade
    4. Employee benefits expense
    5. Depreciation and amortisation expense
    6. Finance cost
    7. Other expenses

Total expenses

  1. Profitl(loss) before tax and exceptional item (I-II) IV Exceptional items
    V Profit/(Ioss) before Tax (I1J+lV) VI Tax expense:
    1. Current tax (net)
    2. Deferred tax chargedl(created)

Total tax expenses

VII Net Profit/(loss) after tax for the period/year (V-VI)

VIII Other comprehensive income1(loss):

  1. i)Items that will not be reclassified to profit or toss
    1. Income tax related to above
  3. i) Items that will be reclassified to profit or loss
    1. Income Tax related to above

IX Total comprehensive income1(lo5s) for the period/year (VII+VIII)

  1. Total comprehensive income/(Ioss) attributable to:
    1. owners of the Company
    2. Non-controllinginterests

XI Paid-up equity share capital (face value ofRe. 1/- each) XII Other equity

XIIJ Earningl(loss) per share, (annualised, except for quarters) Basic and Diluted (in Rs.}

Statement of Standnlcnc and Consolidated Financial Results (Audited)

for the Quarter and Year ended March 31, 2023

{Rs. in Lakh except per share;

Standalone

Consolidated

Quarter Ended

Year Ended

Quarter Ended

Year Ended

March 31,

December

March 31,

March 31,

March 31,

March 31,

December

March 31,

March 31,

March 31,

2023

31,2022

2022

2023

2022

2023

31,2022

2022

2023

2022

Audited

Unaudited

Audited

Audited

Audited

Audited

Unaudited

Audited

Audited

Audited

7,502

7,197

4,150

25,707

23,550

12,893

11,520

14,073

45,995

66,123

1,027

971

257

3,443

1,257

1,506

1,394

405

5,166

1,097

8,529

8,168

4,407

29,150

24,807

14,399

12,914

14,478

51,161

67,220

3,616

2,850

2,373

13,116

17,240

5,951

4,807

5,233

21,103

28,125

75

-

75

64

-

196

492

726

2,992

(600)

(23)

(1,080)

3,115

(6,095)

(203)

(225)

1,185

3,437

(4,897)

1,903

1,749

1,855

7,103

7,250

3,055

3,202

4,713

12,648

18,297

590

608

706

2,450

2,643

951

967

1,115

3,912

4,378

270

268

144

1,006

704

105

96

3,066

444

18,084

2,165

1,392

2,940

8,560

12,359

4,657

4,404

5,469

17,877

22,926

8,019

6,844

6,938

35,425

34,165

14,516

13,447

21,273

60,147

89,905

510

1,324

(2,531)

(6,275)

(9,358)

(117)

(533)

(6,795)

(8,986)

(22,685)

-

-

1,938

2,777

167,621

10,266

167,621

510

1,324

(2,531)

(6,275)

(9,358)

1,821

2,244

160,826

1,280

144,936

-

-

-

-

-

i

-

256

40,073

256

40,089

2,479

-

2,479

-

2,833

307

(2,994)

4,399

(2,987)

2,479

-

-

2,479

-

3,089

307

37,079

4,655

37,102

(1,969)

1,324

(2,531)

(8,754)

(9,358)

(1,268)

1,937

123,747

(3,375)

107,834

(180)

-

68

(190)

50

(66)

(21)

(27)

(137)

(30)

-

-

-

-

-

(28)

5

20

(13)

20

-

-

-

183

-

(30)

178

(30)

-

-

-

-

-

(2,149)

1,324

(2,463)

(8,944)

(9,308)

(1,179)

1,921

123,710

(3,347)

107,794

(2,149)

1,324

(2,463)

(8,944)

(9,308)

(1,152)

1,920

123,705

(3,296)

107,792

-

-

-

(27)

I

5

(51)

2

613

613

613

613

613

613

613

613

613

613

31,953

40,897

-

-

-

83,748

87,051

(3.21)

2.16

(4.13)

(14.29)

(15.28)

(2.07)

3.16

202.03

(5.51)

176.05

--

~

l

Statement of Standalone and Consolidated Financial Results (Audited) for the Quarter and Year ended March 31. 2023

Audited Segment-wiseRevenue, Results and Capital Employed

Particulars

Consolidated

Quarter Ended

Year Ended

March 3t,

December

March 31,

March 31,

Man-h31,

2023

31

2022

2022

2023

2022

Audited

Unaudited

Audited

Audited

Audited

a) Segment revenue

  1. Vaccines
  2. Formulations Sub total
    Less: Inter segment revenue Total segment revenue

b) Segment results

Profit (+)/10" (-) before tax

  1. Vaccines
  2. Formulations Subtotal
    Other unallocated expenditure net of unallocated income and exceptional items

Total Profltqloss} before tax

c) Capital employed

Segment assets

  1. Vaccines
  2. Formulations SubTotal Segment liability
  1. Vaccines
  2. Formulations Sub Total

Capital employed (Segment assets - segment liabilities)

(i) Vaccines

I nn Formulations

Total capital employed

•••. v ••.• ouv .•••...• 0.... .... "' ...~~." ~.A~" 'fi••• "•.••• " •••..••.•••.•• "••••....

Particulars

  1. Segment revenue
    (i) Vaccine
  1. Formulations Total
  1. Segment results (Profit (+)11 oss (-) before tax) 0) Vaccine
  1. Formulations Total
  1. Segment assets
  1. Vaccine
  2. Formulations

Total

  1. Segment liabilities
    (i) Vaccine
  1. Formulations Total

7,501

7,190

4,150

25,699

23,477

5,392

4,330

9,923

20,296

42,646

12,893

11,520

14,073

45,995

66,123

-

66,123

12,893

11,520

14,073

45995

926

529

(2,110)

(6,488)

(8,935)

895

1,715

162,936

7,768

153,871

1,821

2,244

160,826

1,280

144,936

-

1,821

2,244

160,826

1,280

144,936

73,980

72,789

72,193

73,980

72,193

'

52,536

60,997

99,694

52,536

99,694

I

126,516

133,786

171,887

126516

171,887

29,853

28,013

23,861

29,853

23,861

13,042

23,831

64,400

13,042

64,400

42895

51,844

88,261

42,895

88,261

44,127

44,776

48,332

44,127

48,332

39,494

37,166

35,294

39,494

35,294

83,621

81,942

83,626

83,621

83,626

Consolidated

Quarter Ended

Year Ended

March 31,

December

March 31,

March 31,

March 31,

2023

31,2022

2022

2023

2022

Audited

Unaudited

Audited

Audited

Audited

-

-

-

-

-

-

-

-

-

-

-

-

-

600

600

4,000

600

4,000

-

600

600

4,000

600

4,000

210

210

260

210

~60 i

-

260 I

210

210

260

210

~

Statement

of Assets

and Liabilities

{Rs. in Lakh)

Standalone

Consolidated

Particulars

As at

As at

As at

As at

March 31,

March 31,

March 31,

March 31,

2023

2022

2023

2022

Audited

Audited

Audited

Audited

ASSETS

(1) Non-current assets

38,526

41,607

58,833

62,060

a) Property, plant

and equipment

b) Capital work

in

progress

1.642

86

2,801

491

c) Other

Intangible

assets

6

6

1.162

147

d) Intangible

assets

under development

1,142

I

1,432

1,235

e) Investment

Property

5,004

3.790

f) Financial Assets

27

27

7

7

i) Investment

ii)

Loans

35

8

30

8,481

iii)

Others

financial

asset

255

154

489

g) Deferred tax asset (net)

-

2,375

h) Non-current

tax asset

350

242

601

562

i) Other

non-current

assets

4,890

1,380

4.930

1,474

Sub-total

51877

47,301

70.285

76,832

(2) Current assets

11,610

12,925

20,209

21,272

a) Inventories

b) Financial

Assets

-

1,342

500

i) Investments

ii) Trade receivables

1,227

2,332

6,009

8,166

iii) Cash and cash equivalents

601

533

3,985

5,035

iv)

Bank balance

other than cash and cash equivalent

3,724

3,735

18,614

53,293

v) Loans

81

85

158

144

vi)

Others

financial

assets

21

32

249

408

c) Other

current

assets

2,650

5,240

5,665

6,237

Sub-total

19,914

24,882

56,231

95,055

Assets

classified

as held for sale

600

4,000

600

4,000

T oral

Assets

72,391

76183

127,116

175887

EQUITY AND LIABILITIES

Equity

613

613

613

613

a) Equity share capital

b) Other equity

31,953

40,897

83,748

87,051

Sub-total

32566

41,510

84,361

87,664

Non-c:ontrolling

Interest

-

-

(350)

(298)

LIABILITIES

  1. Non-currentliabilities
  1. Financial liabilities

i) Borrowings

10,240

8,410

2,016

3,410

(ii) Other financial

liabilities

541

13

-

2,916

b) Provisions

1,270

1,330

2,655

c) Deferred tax liability (net)

2,479

2,037

4,559

d) Other non-current

liabilities

245

3,214

  1. Current liabilities a) Financial liabilities

i) Borrowings

6

5

6

5

ii) Trade payables.

188

155

531

372

Total outstanding

dues of micro

and small

enterprises

Total outstanding

dues of other

creditors

12,724

14,339

17,201

23,100

iii) Other financial liabilities

2,017

461

2,036

517

(b) Other current liabilities

7,276

6,569

9,529

49,778

(c) Provisions

2,874

2,886

3,614

3,595

(d) Current tax liabilities

(net)

56

9

Sub-total

39,615

34,413

42,895

88,261

Liabilities directly

associated with discontinued

operations

210

260

210

260

Total Eauitv and

Liabilities

. 72,391

76,183

121,116

175,887

~7

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Panacea Biotec Ltd. published this content on 29 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 June 2023 13:40:08 UTC.